Avena sativa
Avena sativa has been studied in 3 papers since 2022: 2 trials in people, 1 review; 1 in the past year. The newest paper, Feb 18, 2026: “Changes of gut microbiota, hormone and glycolipid metabolism by dietary fiber (oat bran) supplementation in patients with laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass: A randomized controlled study”.
3 papers study it8 findingsUpdated
“Compared to baseline, the iAge® at 2 weeks post intervention showed a trend toward a decrease in iAge® in the oat treatment (OBG) group, although this was not statistically significant.”
1 of its findings points the other way.
- 2 independent labs in 2 countries
- 1 finding against
- Funder: PepsiCo
- 4 of 8 findings with company ties
- Human trial2
Studies in people
2 studies gave avena sativa to people and measured what changed.
up: Increases GLP-1
down: Decreases fasting blood glucose
no change: Has no effect on excess weight loss16.59 ± 5.87% vs 10.47 ± 3.29%
Randomized trial63 people12 weeks
Post-BS patients
Nutrition (Burbank, Los Angeles County, Calif.), Feb 18, 2026
no change: Has no effect on iAge
down: Decreases iAge−1.46 iAge years
down: Decreases CCL11−7% change
Randomized trial191 people38% male21–65 years old (average age of 48)four weeks
Healthy male and female patients with moderate-to-elevated LDL-cholesterol levels
Nutrients, Oct 25, 2022
What did studies of Avena sativa find?
5Studies of Avena sativa measured 5 outcomes; the most studied are iAge (1 study), excess weight loss (1) and fasting blood glucose (1).
iAge
downin humans1no changein humans1
1 study
iAge
downin humans1no changein humans1
Avena sativa decreases iAge in high baseline iAge group (>49.6 years) (−1.46 iAge years).
“The high iAge® group exhibited a significant decrease in iAge® at week 2 (−1.46 iAge years, p = 0.008), whereas no significant change was observed in the low iAge® group ( A,B).”
Human trialin high baseline iAge group (>49.6 years)four weeks
Nutrients
Avena sativa showed no clear effect on iAge in whole sample at 2 weeks.
“Compared to baseline, the iAge® at 2 weeks post intervention showed a trend toward a decrease in iAge® in the oat treatment (OBG) group, although this was not statistically significant.”
Human trialin whole sample at 2 weeksfour weeksn = 191
Nutrients
Avena sativa decreases iAge in subjects with elevated levels of iAge® at baseline (>49.6 iAge® years).
“A beneficial effect of the oat product was observed in subjects with elevated levels of iAge® at baseline (>49.6 iAge® years) as early as two weeks post-treatment.”
Human trialin subjects with elevated levels of iAge® at baseline (>49.6 iAge® years)oat productserum3 g of β-Glucantwo weeks
Nutrients
Excess weight loss
no changein humans1
1 study
Excess weight loss
no changein humans1
Avena sativa showed no clear effect on excess weight loss in humans (post-BS patients) (16.59 ± 5.87% vs 10.47 ± 3.29%).
“Although the between-group difference in EWL% was not statistically significant (16.59 ± 5.87% vs 10.47 ± 3.29%, P > 0.05)”
Human trialpost-BS patients30 g/d oat bran (9.0 g DF)12 weeksn = 63
Nutrition (Burbank, Los Angeles County, Calif.)
Fasting blood glucose
downin humans1
1 study
Fasting blood glucose
downin humans1
Avena sativa decreases fasting blood glucose in humans (post-BS patients).
“The intervention group showed significant improvements in fasting GLP-1 and PYY, FBG, and HDL-C (P < 0.05).”
Human trialpost-BS patients30 g/d oat bran (9.0 g DF)12 weeksn = 63
Nutrition (Burbank, Los Angeles County, Calif.)
GLP-1
upin humans1
1 study
GLP-1
upin humans1
Avena sativa increases GLP-1 in humans (post-BS patients).
“The intervention group showed significant improvements in fasting GLP-1 and PYY, FBG, and HDL-C (P < 0.05).”
Human trialpost-BS patients30 g/d oat bran (9.0 g DF)12 weeksn = 63
Nutrition (Burbank, Los Angeles County, Calif.)
CCL11
downin humans1−7% change
1 study
CCL11
downin humans1−7% change
Avena sativa decreases CCL11 in high baseline iAge group (>49.6 years) (−7% change).
“Similarly, the high iAge® group in the OBC group showed a significant decrease in CCL11 at week 2 (−7% change, p = 0.002), but no significant decrease was observed in the low iAge® group ( E,F).”
Human trialin high baseline iAge group (>49.6 years)four weeks
Nutrients
What is Avena sativa linked with?
1Studies link Avena sativa with 1 measure, most often microbiome composition (1 study).
Microbiome composition
mixedin humans1
1 study
Microbiome composition
mixedin humans1
Avena sativa is associated with microbiome composition in humans (post-BS patients).
“with increased beneficial genera (Lachnospira, Parabacteroides) and reduced Streptococcus (P < 0.05).”
Human trialpost-BS patients30 g/d oat bran (9.0 g DF)12 weeksn = 63
Nutrition (Burbank, Los Angeles County, Calif.)